Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 8Neoplasms 4Pancreatic Neoplasms 3Adenoma, Islet Cell 3Carcinoma 2Carcinoid Tumor 2Adenoma 2Pancreatic Neuroendocrine Tumors 1Pancreatic Diseases 1Neuroectodermal Tumors, Primitive 1Neuroectodermal Tumors 1Neoplasms, Nerve Tissue 1Neoplasms, Glandular and Epithelial 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Metastatic Digestive System Neuroendocrine Tumor G1 1Gastro-enteropancreatic neuroendocrine tumor 1Endocrine System Diseases 1Endocrine Gland Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Neuroendocrine 1Adenocarcinoma 1

Interventions

Everolimus 2trifluridine tipiracil drug combination 1pegfilgrastim 1gallium Ga 68 dotatate 1fosbretabulin 1dactolisib 1Temozolomide 1TH 302 1Sunitinib 1Nivolumab 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive × Sunitinib × NET × Clear all
NCT02402062 2020-07-27

A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
17 enrolled 55 charts
EndocrineGastrointestinalNET

Pancreatic Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡